Imlunestrant Makes ESR1 Testing Actionable in Breast Cancer
Episode Summary
FDA approved imlunestrant plus abemaciclib for ESR1-mutated advanced breast cancer after endocrine progression, making biomarker testing central to treatment selection and monitoring.